泰容产投成为太龙药业控股股东的时间并不长。2021年11月29日，郑州众生实业集团有限公司（以下简 称众生实业）与泰容产投签署股份转让协议，泰容产投受让众生实业持有的8244.12万股太龙药业股 份，占其总股本的14.37%，转让价款合计约8亿元。2022年1月，该交易完成过户，太龙药业控股股东 正式由众生实业变更为泰容产投，实控人变更为郑州高新技术产业开发区管委会，跻身国有控股企业行 列。 12月1日晚，河南太龙药业股份有限公司（以下简称太龙药业）发布公告，控股股东郑州泰容产业投资 有限公司（以下简称泰容产投）正在筹划公司股份转让事宜，该事项可能导致公司控制权发生变更。公 司股票自12月2日（星期二）开市起停牌，预计停牌时间不超过2个交易日。这家河南省医药行业首家上 市公司或将迎来近四年内的第二次控制权变动。 太龙药业1993年建厂，1999年在上交所上市，是河南省医药行业首家上市公司，目前主要包含药品制 剂、中药饮片、药品研发服务和药品药材流通四个业务板块。其中，药品制剂业务以中药口服制剂为 主，双金连合剂、双黄连口服液（儿童型）、双黄连合剂及小儿复方鸡内金咀嚼片为公司独家产品/剂 型。 值得注意的是，目 ...

按照此前披露的权益变动报告书，泰容产投将在资金、资源和产业整合方面为上市公司赋能增量，推动 太龙药业在中医药、CXO、大健康等领域的战略发展与实施。 太龙药业主营药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通 四个业务板块。其中，药品制剂业务以中药口服制剂为主，双金连合剂、双黄连口服液（儿童型）、双 黄连合剂及小儿复方鸡内金咀嚼片为公司独家产品/剂型；中药饮片业务由全资子公司桐君堂开展，目 前经营有700多个品种、1100多个品规；药品研发服务业务主要由子公司北京新领先开展，为制药企业 和新药研发机构提供临床前药学研究、临床CRO研究、申报注册等药品研发全过程专业技术服务。 12月1日晚间，太龙药业(600222)发布公告称，控股股东郑州泰容产业投资有限公司（以下简称"泰容产 投"）正在筹划股份转让事宜，可能导致公司控制权变更。 鉴于上述事项尚存在不确定性，为避免造成股价异常波动，太龙药业将自2025年12月2日起停牌，预计 停牌时间不超过2个交易日。 二级市场方面，太龙药业近两个交易日涨幅明显，分别上涨5.37%、6.72%，最新报收8.58元/股，市值 49.2亿元。 截至 ...

Investment Rating - The report assigns an "Accumulate" rating for the company [4] Core Viewpoints - The company benefits from the revival of traditional Chinese medicine, with stable core business and a strong moat for its "Shuanghuanglian" product series, which is expected to benefit from differentiation, segmentation, and upgrading trends [3] - The new controlling shareholder has strong background and capabilities, which will enhance resource matching, management models, and development strategies, promoting long-term and sustainable growth [3] Financial Performance Summary - Revenue is projected to reach CNY 2,070 million in 2023, with a year-on-year growth rate of 5.6%, followed by a decline of 6.2% in 2024, and then a recovery with growth rates of 9.8%, 10.1%, and 10.0% in the subsequent years [1] - Net profit attributable to shareholders is expected to grow significantly from CNY 44 million in 2023 to CNY 116 million by 2027, reflecting a year-on-year growth rate of 160.3% in 2023 and steady growth thereafter [1] - The company's return on equity (ROE) is projected to improve from 2.8% in 2023 to 6.4% by 2027 [1] Business Segments Summary - The company has a diversified business layout, including drug manufacturing and research services, with a focus on traditional Chinese medicine [12] - The "Shuanghuanglian" oral liquid is a leading product, capturing over 30% market share in 2023, with sales exceeding CNY 700 million [2] - The company’s CRO (Contract Research Organization) business is expected to experience growth due to favorable regulatory changes and increased demand for drug research services [2][3] Market Position and Competitive Landscape - The company ranks third in the market for cold medicine in public medical institutions, with a significant presence in the hospital sector [38] - The recent national centralized procurement is expected to enhance the company's market position, as the selected prices for its products remain stable, indicating limited impact on pricing [2][59]